Диссертация (Эндоскопическая диагностика и лечение обструктивных осложнений брахитерапии рака простаты), страница 20

— 2015. — Vol.22. — №6. — P.8079-8084.107. Outcomes after urethroplasty for radiotherapy induced bulbomembranousurethral stricture disease / Hofer M.D., Zhao L.C., Morey A.F, Scott J.F. [et al.] // Journalof Urology. — 2014. – Vol. 191(5). – P.1307-1312.122108. Oyama, N. Alpha 1-adrenoceptor blocker may improve not only voiding butalso storage lower urinary tract symptoms caused by (125) I brachytherapy for prostatecancer / Oyama N., Aoki Y., Ito H. // ISRN Urol. — 2014. —Vol.30.

— 2014:140654.109. Pagano M.J. Laser ablation in the management of obstructive uropathy inneonates / Pagano M.J., van Batavia J.P., Casale P. // J Endourol. — 2015. — 29(5). —Р.4-611.110. Pasteau, O. De L'emploi du radium dans le traitement des cancers de laprostate / O.

Pasteau, P. Degrais // J. Urol. Med. Chir. — 1913. — Vol. 4. — N 1. —Р. 341-366.111. Patient-reported outcomes and health-related quality of life in prostatecancer treated with a single fraction of high dose rate brachytherapy combined withhypofractionated external beam radiotherapy / Choudhury A, Arthur C, Malik J.

[et al.] //Clin Oncol (R Coll Radiol). — 2014. — Vol.26 (10). — P.661-667.112. Petasecca, M. BrachyView: proof-of-principle of a novel in-body gammacamera for low dose-rate prostate brachytherapy / Petasecca M. // Med. Phys. — 2013. —Vol.40. — №4. — 041709.124.113. Peters, M. Urethral and bladder dosimetry of total and focal salvage Iodine125 prostate brachytherapy: Late toxicity and dose constraints / Peters M, van der Voortvan Zyp J, Hoekstra C. // Radiother Oncol.

— 2015. — Vol.117. — №2. — P.262-269.114. Pham, Y.D. Outcomes for prostate glands >60 cc treated with low-dose-ratebrachytherapy / Pham Y.D., Kittel J.A., Reddy C.A. // Brachytherapy. 2016. —Vol.15(2). – P. 163-168.115. Post-brachytherapy transurethral resection of the prostate in patients withlocalized prostate cancer / T.A. Flam, M. Peyromaure, L. Chauveinc [et al.] // J. Urol. —2004. — Vol. 172. — N 1.

— P. 108-111.116. Prediction of urinary symptoms after125Iodine prostate brachytherapy /K. Kelly, R. Swindell, J. Routledge [et al.] // Clin. Oncol. — 2006. — Vol. 18. — P. 326332.117. Predictive Factors for Prolonged Urination Disorder After Permanent 125IBrachytherapy for Localized Prostate Cancer / Hidehisa M., Tomoharu F., Kei D. [et al.]123// In Vivo. — 2017. – Vol.31(4). – P.755–761118. Predictivefactorsbrachytherapy with orforwithouturinarytoxicityafteriodine-125prostatesupplemental external beam radiotherapy/Eriguchi T., Yorozu A., Kuroiwa N., Yagi Y [et al] // Brachytherapy. — 2016.

—Vol. 15(3). – P. 288-295.119. Predictive factors of rectal toxicity after permanent iodine-125 seedimplantation: Prospective cohort study in 2339 patients / Katayama N., Yorozu A., MaruoS., Kojima S. [et al.] // Brachytherapy. — 2016. – Vol.15(6). – P. 736-745.120. Price, J.G. Predictive factors and management of rectal bleeding side effectsfollowing prostate cancer brachytherapy / Price J.G., Stone N.N., Stock R.G. //International Jornal of Radiation Oncology Biology Physics. — 2013.

— Vol. 86(5). –P. 842-847.121. Prophylactic versus therapeutic alpha-blockers after permanent prostatebrachytherapy / G.S. Merrick, W.M. Butler, K.E. Wallner [et al.] // Urology. —2002. —Vol. 60. — N 4. — P. 650-655.122. Prospective Phase 2 Trial of Permanent Seed Implantation ProstateBrachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, andQuality of Life Outcomes / Frank S., Pugh T., Blanchard P.

[et al.] // Int. J. Radiat. Oncol.Biol. Phys. — 2018 – Vol.100(2). – P. 374–382.123. Prostate high dose-rate brachytherapy as monotherapy for low andintermediate risk prostate cancer: Early toxicity and quality-of life results from arandomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy /Morton G., Chung H.T., McGuffin M., Helou J. [et al.] // Radiotherapy Oncology. —2017.

– Vol.122(1). – P.87-92.124. Quality of life after radical radiotherapy for prostate cancer: longitudinalstudy from a randomised trial of external beam radiotherapy alone or in combination withhigh dose rate brachytherapy / Hoskin P.J., Rojas A.M., Ostler P.J. [et al.] // Clin. Oncol.(R Coll. Radiol). — 2013. — Vol.25 (5). — P.321-327125. Quality of life impact of treatments for localized prostate cancer: cohortstudy with a 5 year follow-up / Ferrer M., Guedea F., Suárez J.F. [et al.] // Radiother.124Oncol. — 2013. — Vol. 108 (2).

— P. 306-313.126. Ragde, H. Brachytherapy for clinically localized prostate cancer / H. Ragde,L. Korb // Semin. Surg. Oncol. — 2000. — Vol. 18. — Р. 45-51.127. Rectal ulcers and rectoprostatic fistulas after (125)I low dose rate prostatebrachytherapy / Leong N., Pai H.H., Morris W.J., Keyes M. [et al.] // Journal Urology. —2016.

– Vol.195(6). P.-1811-1816.128. Risk of incontinence with transurethral resection of the prostate afterradiation therapy for prostate cancer / H. Patel, A.V. Peddada, P.E. Zimmern [et al.] // J.Surg. Oncol. — 1997. — Vol. 64. — P. 127.129. Risk of urinary incontinence following post-brachytherapy transurethralresection of the prostate and correlation with clinical and treatment parameters / S. Mock,M. Leapman, R.G.

Stock, [et al.] // J. Urol. — 2013, Nov. — Vol. 190. — N 5. — P.1805-1810.130. Rourke,K.Observationsandoutcomesofurethroplastyforbulbomembranous stenosis after radiation therapy for prostate cancer / Rourke K.,Kinnaird A., Zorn J. // World J Urol. — 2016. — Vol.34. — №3. — P.377-382.131. Sachse, H. Die sichturethrotomie mit scharbem schnitt. Operative technik –indikation, komplikationen, ergebnisse / Sachse H. // Kongre Bbericht InternationalesSymposium. Wien. — 1979. — P.

11-14.132. Schiffmann, J. Additional androgen deprivation makes the difference:Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapyand external beam radiotherapy / Schiffmann J., Lesmana H., Tennstedt P. // StrahlentherOnkol.

— 2015. — Vol.191. — №4. — P.330-337.133. Severe rectal complications after prostate brachytherapy / Wallner K, SutliefS, Bergsagel C, Merrick GS. // Radiotherapy and Oncology. — 2015. – Vol. 114(2). –P.272-275.134. Sexual potency preservation and quality of life after prostate brachytherapyand low-dose tadalafil Pugh T.J., Mahmood U., Swanson D.A. [et al.] // Brachytherapy.— 2015. —Vol.14. — №2. —P.160-165.135.

SIU/ICUD Consultation on Urethral Strictures: Posterior urethral stenosis125after treatment of prostate cancer / Herschorn S, Elliott S, Coburn M. [et al.] //Urology. — 2014. — Vol.83 (3 Suppl). — Р.59-70.136. Skowronek, J. Brachytherapy in the therapy of prostate cancer - aninteresting choice / Skowronek J.

// Contemp. Oncol. — 2013. — 17(5). — P.407–412.137. Skowronek, J. Low-dose-rate or high-dose-rate brachytherapy in treatmentof prostate cancer - between options / Skowronek J. //. J. Contemp. Brachytherapy. —2013. — Vol.5. — №1. — P.33–41.138. Stone, NN. Prostate brachytherapy in men with gland volume of 100cc orgreater: Technique, cancer control, and morbidity / Stone N.N., Stock R.G. //Brachytherapy. — 2013. — Vol.12 (3).

— P.217-221.139. Tanaka, N. The biochemical recurrence-free rate in patients who underwentprostate low-dose-rate brachytherapy, using two different definitions / Tanaka N.,Asakawa I., Katayama E. // Radiat Oncol. — 2014. — Vol.6 (9). — P.107.140. The influence of isotope and prostate volume on urinary morbidity afterprostate brachytherapy / A. Niehaus, G.S. Merrick, W.M. Butler, [et al.] // Int.

J. Radiat.Oncol. Biol. Phys. — 2006. — Vol. 64. — N 1. — P. 136-143.141. The use of a memokath prostatic stent for obstructive voiding symptomsafter brachytherapy / de Graaf GW, Stijns PE., Scheepens WA. [et al.] // Curr Urol. —2013. — Vol.7 (1). — P.19-23.142. Treatment of Urethral Strictures from Irradiation and Other NonsurgicalForms of Pelvic Cancer Treatment / Khourdaji I., Parke J., Chennamsetty A., Burks F. //Advences in Urology. — 2015. – 476390.143. Urethral stricture after radiation therapy / Rosenbaum C.M., Engel O., FischM., Kluth LA. // Der Urologe. — 2017.

– Vol. 56(3). – P. 306–312.144. Urethral stricture following high dose rate brachytherapy for prostate cancer/ Sullivan L., Williams S.G., Tai K.H., Foroudi F. [et al.] // Radiotherapy andOncology. — 2009. – Vol. 91(2). – P. 232-236.145. Urethral toxicity after LDR brachytherapy: experience in Japan / Tanaka N.,Asakawa I., Hasegawa M., Fujimoto K. // Brachytherapy. — 2015. — Vol.14 (2). —P.131-135.126146. Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 ImplantBrachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional ProspectiveCohort Study / Ohashi T., Yorozu A., Saito S., Tanaka N.

[et al.] // Int. J. Radiat. Oncol.Biol. Phys. — 2015. – Vol. 93(1). – P.141-149.147. Use of holmium laser for urethral strictures in pediatrics: A prospective study/ Shoukry A.I., Abouela W.N., El Sheemy M.S. [et al.] // J. Pediatr. Urol. — 2016. —Vol.12 (1). — №42. — Р. 1-6.148. Waterman, F.M. Impact of postimplant edema on V(100) and D(90) inprostate brachytherapy: can implant quality be predicted on day 0? / F.M. Waterman,A.P.

Dicker // Int. J. Radiat. Oncol. Biol. Phys. — 2002. —Vol. 53. — N 3. — P. 610621.149. Whitmore, W.F. Interstitial radiation therapy for carcinoma of the prostate /W.F. Whitmore // Prostate. — 1980. — Vol. 1. — P. 157-168.150. Yang, G. Dosimetric coverage of the prostate, normal tissue sparing, andacute toxicity with high-dose-rate brachytherapy for large prostate volumes / Yang G.,Strom T.J., Wilder R.B.

// Int Braz J Urol. — 2015. — Vol.41 (3). — P.435-441.151. Yutkin, V. Salvage high-intensity focused ultrasound for patients withrecurrent prostate cancer after brachytherapy / Yutkin V., Ahmed H.U., Donaldson I. //Urology. — 2014. — Vol.84 (5). — Р.1157-1162.152. Zhang, YY. Early channel transurethral resection of the prostate for patientswith urinary retention after brachytherapy / Zhang Y.Y., Zhang Z.G., Yu Y.L. // JZhejiang. Univ. Sci. B. — 2014. — Vol.15 (8). — P.756-760..